Abstract library

1809 results for "Patient MDT".
#54 The clinical challenge of patients with a thoracic or neck neuroendocrine tumor: a retrospective analysis from a single Irish institution
Introduction: Thoracic and neck neuroendocrine tumors (T-N-NETs) represent a rare and intriguing condition and the management of patients with a NET localized at the thorax or neck can be extremely problematic. An expert and multidisciplinary approach is generally required for the optimal management of NET patients. A systematic multidisciplinary approach to NET patients has been recently established at our institution.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Gianluca Tamagno
#1525 Retrospective Review of Single Centre’s Experience of the Side Effects Reported by Patients Receiving Everolimus and the Potential Implications Relating to Patient Monitoring and Education
Introduction: Everolimus, an mTOR inhibitor, is a recommended therapy for patients with pancreatic neuroendocrine tumours. It has recognised toxicity profile.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Philippa Davies
Authors: Davies P, ...
#1767 International Patient Survey of Physical, Emotional and Informational Challenges when Living with NETs: Understanding the Unmet Needs
Introduction: The usefulness of information sources used by NET patients is rarely explored by patient surveys of disease burden/impact on daily living, and may be key to optimizing care.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Mohid Khan
Authors: Khan M, Majdi A, Goldstein G, Mellar K, ...
#209 A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by Either Self/Partner or Healthcare Professional
Introduction: Ready-to-use Lanreotide Autogel provides the option of self/partner administration for patients with NET. This is anticipated to reduce treatment cost and negative impact on daily life.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MSc Anders Öhberg
#2090 Financial Toxicity in Patients with Neuroendocrine Tumor Disease. A so far Underestimated "Side Effect" of Cancer in Germany?
Introduction: Cancer is not only associated with physical and psychological, but also financial burden. In contrast to other countries, the socio-economic impact of cancer for patients in Germany, with a third party paid health care system, is poorly understood.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof.Dr.Dr. Eva Caroline Winkler
#2263 Patient Survey Devoted to Characterizing Experience and Expectations of Patients with Neuroendocrine Tumors (NET)
Introduction: Patients (pts) with NET experience consequences of disease progression and treatments; their preferences can influence the choice and success of therapeutic strategies.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr Matthieu Sarabi
Authors: Sarabi M, Gueguen D, Walter T, Hentic O, ...
#441 Tie-2 and Angiopoietin-2 Plasma Levels as New Diagnostic Markers for Patients with Neuroendocrine Tumors. Data from One Clinical Center
Introduction: Data concerning circulating levels of the angiogenic factors in patients with neuroendocrine tumors (NET) still remain insufficient.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Gabriela Melen-Mucha
#1342 To Evaluate Patient’s Understand of the Neuroendocrine (NET) Multidisciplinary Team (MDT) Meeting Process at a ENETs Centre of Excellence
Introduction: Multidisciplinary teams serve to streamline the patient journey by developing individual treatment plans that are based on ‘best practice'. National and local guidelines govern the MDT process. There is little focus on the patient’s understanding and expectations of how and when the MDT recommendations are communicated.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Miss Christina Rigby
Authors: Rigby C, ...
Keywords: Patient MDT
#2100 OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Neuroendocrine Tumors Starting Lanreotide – Study Design
Introduction: Information provided to patients about burden and treatment of neuroendocrine tumors (NETs) may ease treatment adherence, outpatient monitoring, and improve quality of life (QoL), but can also cause anxiety. Data on how to individually adapt materials are insufficient and mainly derived from clinical trials.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Vincent Hautefeuille
Authors: Gueguen D, Hammel P, ...
#614 The Effect of Patient and Doctors Delay in Patients with Neuroendocrine Tumors
Introduction: The diagnosis of neuroendocrine tumors (NET) is often delayed due to the vague symptoms and rareness of the disease.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Catharina M Korse
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.